This proposal is designed to further develop three types of vaccine candidates: recombinant stress protein fusions, HIV and SIV genome-less particles, and live recombinant BCG vehicles that express antigens and lymphokines. We plan to engineer novel recombinant fusion proteins that incorporate mycobacterial stress proteins and retroviral proteins, exploiting the unusual immunological properties of stress proteins. We will continue to develop genetically inactivated HIV/SIV particles as vaccine candidates by constructing stable cell lines that produce the noninfectious retroviral mutants particles. We will also continue to generate and test the immune response to new forms of recombinant BCG vaccines, especially those that secrete interleukin. We are undertaking the simultaneous development of these three vaccine candidates because we recognize that an efficacious HIV vaccine may require multiple components. Our strategy is to investigate the humoral and cellular immune response to each reagent in mice, to optimize conditions required for eliciting CD8+ CTL, and to provide these data and reagents to investigators in other NCVDG programs and at NIAID for further studies in primates. The stress protein fusions, genetically inactivated retroviral particles, and BCG recombinants will be provided to specific NCVDGs and to NIAID for tests of efficacy in animal models. A vaccine study with BCG-SIV recombinants is already underway in collaboration with the NCVDG under Dr. Murray Gardner. The long-term goals of this research program are to improve our understanding of HIV biology and immunology and to develop an HIV vaccine candidate.

Project Start
Project End
Budget Start
Budget End
Support Year
7
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Whitehead Institute for Biomedical Research
Department
Type
DUNS #
076580745
City
Cambridge
State
MA
Country
United States
Zip Code
02142
Segal, A H (1996) Anatomic predilection of the spondyloarthropathies(-)a case of the nerves? J Rheumatol 23:491-4
Burns, D P; Collignon, C; Desrosiers, R C (1993) Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys. J Virol 67:4104-13
Burns, D P; Desrosiers, R C (1992) A caution on the use of SIV/HIV gag antigen detection systems in neutralization assays. AIDS Res Hum Retroviruses 8:1189-92
Javaherian, K; Langlois, A J; Schmidt, S et al. (1992) The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 89:1418-22
Kim, S; Ikeuchi, K; Groopman, J et al. (1990) Factors affecting cellular tropism of human immunodeficiency virus. J Virol 64:5600-4
Kim, S; Ikeuchi, K; Byrn, R et al. (1989) Lack of a negative influence on viral growth by the nef gene of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 86:9544-8